佛慈制药：2024年净利润6006.98万元，同比下降10.60%

Core Viewpoint - The company reported a decline in both revenue and net profit for the year 2024, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for 2024 was 980 million yuan, a year-on-year decrease of 15.73% [1] - The net profit attributable to shareholders was 60.0698 million yuan, down 10.60% compared to the previous year [1] - Basic earnings per share were 0.1176 yuan, reflecting a decline of 10.64% year-on-year [1] Dividend Distribution - The company plans to distribute a cash dividend of 0.12 yuan per 10 shares (tax included) to all shareholders [1] - No bonus shares will be issued, and there will be no capital reserve fund conversion into share capital [1]